Details

Autor(en) / Beteiligte

• Sherman, Kenneth E
• Flamm, Steven L
• Afdhal, Nezam H
• Nelson, David R
• Sulkowski, Mark S
• Everson, Gregory T
• Fried, Michael W
• Adler, Michael
• Reesink, Hendrik W
• Martin, Marie
• Sankoh, Abdul J
• Adda, Nathalie
• Kauffman, Robert S
• George, Shelley
• Wright, Christopher I
• Poordad, Fred

Titel

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

Ist Teil von

• The New England journal of medicine, 2011-09, Vol.365 (11), p.1014-1024

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In patients with chronic infection with HCV genotype 1 and undetectable HCV at weeks 4 and 12 of treatment, a 24-week regimen that included telaprevir, peginterferon, and ribavirin was not inferior to a 48-week regimen. Chronic infection with hepatitis C virus (HCV) represents a serious health issue for nearly 200 million infected persons worldwide. 1 Achievement of a sustained virologic response may be associated with improved long-term clinical outcomes, including increased survival. 2 , 3 In patients infected with HCV genotype 1, 48 weeks of treatment with peginterferon alfa and ribavirin results in a rate of sustained virologic response of 40 to 50%. 4 , 5 Telaprevir administered in combination with peginterferon and ribavirin has led to high rates of sustained virologic response in phase 2 and phase 3 trials involving patients with HCV genotype 1 infection, who have not . . .